Diabetic Gastroparesis Treatment Market

Diabetic gastroparesis refers to cases of the digestive condition gastroparesis that diabetes causes.

During normal digestion, the stomach contracts to help break down food and move it into the small intestine. Gastroparesis disrupts the stomach?s contraction, which can interrupt digestion. Diabetes can cause gastroparesis due to its effects on the nervous system.

Both type 1 diabetes and type 2 diabetes can cause nerve damage. One of the nerves diabetes may damage is the vagus nerve. The vagus nerve controls the movement of food through the stomach. When the vagus nerve experiences damage, the muscles in the stomach and other parts of the digestive tract are not able to function properly. When this happens, food cannot move as quickly through the digestive system. Gastroparesis is also known as delayed gastric emptying.

Diabetic Gastroparesis Treatment Market contains market size and forecasts of Diabetic Gastroparesis Treatment in Global, including the following market information:

Global Diabetic Gastroparesis Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Diabetic Gastroparesis Treatment market was valued at 3496.7 million in 2021 and is projected to reach US$ 5136.1 million by 2028, at a CAGR of 5.6% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Diabetic Gastroparesis Treatment include Sumitomo, Johnson & Johnson, Sanofi, Medtronic, Pfizer, Teva and Boston Scientific, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Diabetic Gastroparesis Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Diabetic Gastroparesis Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Diabetic Gastroparesis Treatment Market Segment Percentages, by Type, 2021 (%)

Drugs

Surgical Treatment Products

Global Diabetic Gastroparesis Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Diabetic Gastroparesis Treatment Market Segment Percentages, by Application, 2021 (%)

Hospital Pharmacies

Private Clinics

Drug Stores

E-Commerce

Global Diabetic Gastroparesis Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Diabetic Gastroparesis Treatment Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Diabetic Gastroparesis Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Diabetic Gastroparesis Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Sumitomo

Johnson & Johnson

Sanofi

Medtronic

Pfizer

Teva

Boston Scientific